TD Cowen initiates BioCryst stock with buy rating on HAE drug outlook

TD Cowen initiated BioCryst Pharmaceuticals with a Buy rating and $30 price target, implying substantial upside from the $9.12 trading price. The firm expects Orladeyo to generate $600M-$800M+ in long-term revenue and sees navenibart potentially reaching $1B in sales, supported by anticipated Phase III data in Q3 2027. BioCryst also beat Q2 2026 expectations with adjusted EPS of $0.30 versus $0.16 consensus and revenue of $218.3M versus $185.7M forecast, while raising full-year revenue guidance and lowering operating-cost guidance.

Analysis

The investable issue is whether BCRX has crossed from a single-asset orphan-drug story into a self-funded HAE platform. If commercial execution continues to fund development without equity issuance, the market can re-rate the equity from a discounted patent-risk multiple toward specialty-pharma peers; the relevant driver is durable net revenue per patient, not the headline patient-retention statistic. The stated revenue figures require verification against filings, however: the apparent mismatch between trailing revenue and the cited quarterly run-rate is material to any valuation conclusion and should be resolved before sizing.

Near term, the upgraded outlook and cost discipline create a 1-3 month estimate-revision setup, particularly if sell-side models have not fully incorporated operating leverage. The more consequential 6-18 month issue is whether oral prophylaxis remains a differentiated submarket as alternatives develop: high retention may indicate switching friction, but it can also reflect selection bias among patients already tolerating and responding to therapy. A successful later-stage pipeline read would create platform optionality, while a weak result would expose the stock to concentration risk and likely return valuation to the mature-asset cash-flow base.

Consensus appears to be anchoring on a large price-target gap rather than assigning explicit probabilities to competitive entry, payer step-edits, and pipeline execution. The upside is therefore underwritten only if management demonstrates stable patient persistence and net pricing through multiple quarters; otherwise, a low sales multiple may be appropriate rather than evidence of mispricing. Watch for sequential prescription growth, gross-to-net deterioration, and any reduction in long-term revenue guidance as the cleanest falsifiers.

Key Decisions for Investors

• Initiate a starter long BCRX only after validating reported revenue, net debt, and cash-flow conversion in the next filing; target a 6-12 month re-rating on upward consensus EPS/revenue revisions, with sizing capped pending confirmation that growth is not primarily inventory or one-time payer timing.
• Add on evidence of two consecutive quarters of stable-to-improving treated-patient growth and no material gross-to-net pressure; reduce if management cuts long-term commercial guidance or if persistence trends deteriorate, as either would impair the terminal-value case.
• For catalyst-oriented capital, treat the Phase III program as a 2027 event-driven watch item rather than buying long-dated optionality today: assess options liquidity and implied volatility closer to data timing, when the probability-weighted incremental value can be measured against the established commercial franchise.
• Use a relative-value hedge if building a larger position: long BCRX versus a diversified biotech ETF such as XBI over 3-6 months, isolating company-specific execution and estimate-revision upside while reducing broad biotech multiple and rate-sensitivity risk.